GSE206931 WDR5 inhibition WIN 3 v 7 human up (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE206931_WDR5 inhibition_WIN_3_v_7_human_up.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE206931_WDR5 inhibition_WIN_3_v_7_human_up.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE206931_WDR5 inhibition_WIN_3_v_7_human_up.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE206931_WDR5 inhibition_WIN_3_v_7_human_up.

Results found

Linked to

 

Label

Description

 

Gene

HERC2 pseudogene 2

Gene

p53 upregulated regulator of p53 levels

Gene

long intergenic non-protein coding RNA 2910

Gene

MIR34A host gene

Gene

pleckstrin homology and RUN domain containing M1 pseudogene 1

Gene

RAB4A antisense RNA 1

Gene

ANXA2R antisense RNA 1

Gene

long intergenic non-protein coding RNA 1451

Gene

profilin 1 pseudogene 2

Gene

SLC39A13 antisense RNA 1

  • Gene

    HERC2 pseudogene 2


  • Gene

    p53 upregulated regulator of p53 levels


  • Gene

    long intergenic non-protein coding RNA 2910



  • Gene

    pleckstrin homology and RUN domain containing M1 pseudogene 1


  • Gene

    RAB4A antisense RNA 1


  • Gene

    ANXA2R antisense RNA 1


  • Gene

    long intergenic non-protein coding RNA 1451


  • Gene

    profilin 1 pseudogene 2


  • Gene

    SLC39A13 antisense RNA 1

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.